APEPTICO Forschung und Entwicklung GmbH is a privately-held development stage biotechnology company in Vienna, Austria, developing peptide-based products targeting life-threatening pulmonary diseases.
R&D:APEPTICO's peptide-based products target life-threatening pulmonary diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction, high altitude pulmonary oedema and PHA type 1, and COVID-19. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of proteins and biopharmaceuticals. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.
Production:Solnatide is a synthetic molecule whose structure is based on the lectin-like domain of human Tumour Necrosis Factor alpha. Solnatide is water soluble and can be administered as aerosol (small droplets of diameter 3 μm or less) directly into the lungs of patients by oral inhalation. Solnatide IMP has been designed for activation of the pulmonary epithelial sodium channel (ENaC) and for the restoration of the injured endothelial-epithelial barrier of pulmonary alveoli.